<div id="readability-page-1"><div><p>(MT Newswires) -- Johnson &amp; Johnson (JNJ) and Roche are among the firms in discussions with Shanghai Henlius Biotech to buy the rights to its HLX43 experimental cancer drug, Bloomberg News reported Tuesday, citing people familiar with the matter.</p><p> If the deal goes through, the Shanghai Fosun Pharmaceutical unit could receive at least several hundred million dollars up front, with potentially more in milestone payments depending on the drug's performance, the unnamed sources told the news outlet.</p><p> HLX43 is in mid-stage testing in China, according to the report.</p><p> Johnson &amp; Johnson, Roche, and Shanghai Henlius Biotech didn't immediately respond to MT Newswires' requests for comment.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p></div></div>

強生

羅氏(ADR)

復宏漢霖

<p>強生和羅氏正在與上海復宏漢霖生物科技進行談判，計劃收購 HLX43 實驗性癌症藥物的權利。如果談判成功，上海復星醫藥可能會獲得數億美元的預付款，以及基於該藥物表現的額外里程碑付款。HLX43 目前正在中國進行中期測試。各公司尚未對該討論發表評論</p>

强生公司正在与其他公司进行谈判，以获得上海复宏汉霖实验性抗癌药的使用权